Trabectedin patent
Splet06. jul. 2010 · Trabectedin has now been developed as a chemotherapy drug and is also known by its brand name, Yondelis, for the treatment of advanced soft tissue sarcoma … Splet23. jan. 2024 · The present invention relates to a trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and a method for manufacturing the same. Specifically, the composition contains trabectedin and a first excipient, the first excipient being selected from one or more of monosaccharide or …
Trabectedin patent
Did you know?
Splet27. jul. 2024 · Patent number: 11260065 Abstract: A stable, ready-to-use injectable solution including thiotepa and one or more pharmaceutically acceptable solvents, co-solvents, and/or solubilizing agents. Formulations retain at least 90% and as high as 99% of the purity of thiotepa as measured by HPLC after storage at 25° C./60% RH for a period of 7 days. Splet10. sep. 2024 · Trabectedin is a vesicant with the potential for extravasation from the blood vessels and subsequent damage to surrounding tissue. Damage may include blistering, …
Splet07. jan. 2024 · Trabectedin (ET‑743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline rings. In the present case report, two patients with advanced and metastatic uterine leiomyosarcomas (ULMS) with significant progression‑free survival … SpletTrabeticidine has strong in vitro activity against multiple tumor cell lines, such as soft tissue sarcoma, leukemia, melanoma, breast cancer, non-small cell lung cancer and …
Spletperipheral venous access, or a patent central line, should be ensured prior to administration. There is no evidence that eribulin mesilate is a vesicant or an irritant. In the event of extravasation, treatment should be symptomatic. For information relevant to the handling of cytotoxic medicinal products see section 6.6. SpletTRABECTEDIN. PDF Supplier PDF. URL Supplier Web Content. US Patent Number. 8895557. Drug Substance Claim. Drug Product Claim. Y. Patent Expiration Date.
Splet23. okt. 2015 · Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims. Pharmaceutical …
Splet14. sep. 2015 · Research and Markets: Trabectedin Patent, Extension and Data Exclusivity Expiry Snapshot September 14, 2015 06:57 AM Eastern Daylight Time. DUBLIN-- (BUSINESS ... cheapest car rental deals+choicescve informationSpletTrabexidine, also known as ascidin 743, Ecteinascidin 743, ET-743, is a tetrahydroisoquinoline derivative with high antitumor activity isolated from the Caribbean … c vein thrombosisSpletNO2008005I1 - trabectedin - Google Patents trabectedin Classifications A61K35/56 Materials from animals other than mammals View 4 more classifications NO2008005I1 … cve is short forSplet11. mar. 2024 · There is one patent protecting this drug and one Paragraph IV challenge. This drug has forty-four patent family members in thirty-six countries. The generic … cheapest car rental christchurch nzSplet08. dec. 2024 · Trabectedin plus PLD was approved to be used in the treatment of patients with platinum-sensitive ROC in 2009. At time when this study was designed, the antiangiogenics represented the new family of drugs approved for the treatment of ovarian cancer. ... Ownership interests; (IP) Intellectual property rights/inventor/patent holder; … cheapest car rental deals+routesSpletTrabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and a method for manufacturing the same JOP20240254A1 ( en ) 2024-04-27 cvek accounting